Latest results FY2026 · Prices updated Oct 30, 2026
HQ: Osaka, OsakaFounded 19473,464 employeesWebsite
A research-oriented pharmaceutical major famous for the innovative anti-cancer drug Opdivo. It focuses on a 'specialty pharma' strategy to develop breakthrough medicines.
Business segments (share of revenue)
Latest results
FY2026
vs. same period a year earlier
Company forecastFY2027
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| Pharmaceutical Business Segment | 100% | ¥515.8B | ¥92.2B | 17.9% |
Close (Oct 30, 2026)
¥2,256+26.8% (1Y)
Ono +26.8% over 1Y, 14.8pt above the industry average (23 companies, +12.0%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2026FY | ¥515.8B | ¥92.2B | ¥69.8B | ¥1.1T | +5.9% |
| 2025FY | ¥486.9B | ¥59.7B | ¥50.0B | ¥1.1T | -3.1% |
| 2024FY | ¥502.7B | ¥159.9B | ¥128.0B | ¥913.7B | +12.4% |
| 2023FY | ¥447.2B | ¥142.0B | ¥112.7B | ¥882.4B | +23.8% |
| 2022FY | ¥361.4B | ¥103.2B | ¥80.5B | ¥739.2B | +16.8% |
| 2021FY | ¥309.3B | ¥98.3B | ¥75.4B | ¥745.4B | — |
Sources: annual securities reports, earnings releases and other public disclosures (Dec 2024)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
